The Future of the Aging Eye
AnnMarie Hipsley, the Founder and CEO of Ace Vision Group (AVG), a Delaware, USA- based company developing innovative therapeutics for age-related ocular dysfunctions, talks to The Ophthalmologist about her background and work with AVG, and the company’s short- and long-term goals.
She explains how the Group has utilized artificial intelligence and virtual reality platforms to develop the Next Gen VisioLite laser, paints a broad picture of the current gaps in available treatment models for age-related eye diseases, such as presbyopia, and goes into detail about how Laser Scleral Microporation Therapeutic Laser Rejuvenation (LSM) eye therapy sits within the future landscape of treatments for these disorders.
Explore More Articles
Dynamic range of focus recovery in presbyopes after laser scleral microporation
While considered by many to be a “normal process of aging,” the loss of the dynamic focusing function of the eye, presbyopia, is a progressive disease of ocular aging. Presbyopia affects approximately 1.8 billion people globally.1 Estimated global annual productivity losses are approximately 0.037% of the global gross domesticproduct in presbyopic adults less than 65 years …
read moreVIDEO: New laser offers further improvement to laser scleral microporation
BOSTON — In this Healio Video Perspective from Eyecelerator@ASCRS, AnnMarie Hipsley, DPT, PhD, and George O. Waring IV, MD, FACS, discuss the latest advances in laser scleral microporation.Hipsley said that the GenII VisioLite laser for laser scleral microporation (LSM) is on the pathway to commercialization and may be available by the end of the year.
read moreImprovement in Accommodation and Dynamic Range of Focus After Laser Scleral Microporation: A Potential Treatment for Presbyopia
Purpose: To examine the ocular changes in accommodation, wavefront aberrations, and dynamic range of focus (DROF) after laser scleral microporation (LSM) for treating presbyopia.
read more